Lexicon Pharmaceuticals Stock Forecast, Price & News

+0.04 (+0.88 %)
(As of 09/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume323,879 shs
Average Volume2.31 million shs
Market Capitalization$661.69 million
P/E Ratio11.74
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive LXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Lexicon Pharmaceuticals logo

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.22 out of 5 stars

Medical Sector

331st out of 1,352 stocks

Pharmaceutical Preparations Industry

157th out of 665 stocks

Analyst Opinion: 3.2Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions

Is Lexicon Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Lexicon Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LXRX, but not buy additional shares or sell existing shares.
View analyst ratings for Lexicon Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Lexicon Pharmaceuticals?

Wall Street analysts have given Lexicon Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Lexicon Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Lexicon Pharmaceuticals' next earnings date?

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Lexicon Pharmaceuticals

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its earnings results on Friday, July, 30th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.03. The biopharmaceutical company earned $0.23 million during the quarter, compared to analyst estimates of $0.03 million. Lexicon Pharmaceuticals had a net margin of 536.83% and a trailing twelve-month return on equity of 27.59%.
View Lexicon Pharmaceuticals' earnings history

How has Lexicon Pharmaceuticals' stock been impacted by Coronavirus?

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, LXRX shares have increased by 101.8% and is now trading at $4.58.
View which stocks have been most impacted by COVID-19

What price target have analysts set for LXRX?

6 Wall Street analysts have issued 1-year price objectives for Lexicon Pharmaceuticals' shares. Their forecasts range from $7.00 to $20.00. On average, they expect Lexicon Pharmaceuticals' share price to reach $12.00 in the next year. This suggests a possible upside of 162.0% from the stock's current price.
View analysts' price targets for Lexicon Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Lexicon Pharmaceuticals' key executives?

Lexicon Pharmaceuticals' management team includes the following people:
  • Lonnel Coats, President, Chief Executive Officer & Director
  • Jeffrey L. Wade, CFO, EVP-Corporate & Administrative Affairs
  • Craig B. Granowitz, Chief Medical Officer & Senior Vice President
  • Brian T. Crum, Secretary, Vice President & General Counsel
  • Alan J. Main, Executive Vice President-CMC & Supply Operations

What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO?

9 employees have rated Lexicon Pharmaceuticals CEO Lonnel Coats on Lonnel Coats has an approval rating of 100% among Lexicon Pharmaceuticals' employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Lexicon Pharmaceuticals' key competitors?

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (5.15%), BlackRock Inc. (3.22%), Vanguard Group Inc. (2.75%), Pinnacle Associates Ltd. (1.52%), Geode Capital Management LLC (0.89%) and State Street Corp (0.72%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer and Lonnel Coats.
View institutional ownership trends for Lexicon Pharmaceuticals

Which institutional investors are selling Lexicon Pharmaceuticals stock?

LXRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Morgan Stanley, Renaissance Technologies LLC, Bank of America Corp DE, AXA S.A., Squarepoint Ops LLC, and Bridgeway Capital Management LLC.
View insider buying and selling activity for Lexicon Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Lexicon Pharmaceuticals stock?

LXRX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, State Street Corp, Wells Fargo & Company MN, Nuveen Asset Management LLC, Geode Capital Management LLC, Northern Trust Corp, and Swiss National Bank. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, and Lonnel Coats.
View insider buying and selling activity for Lexicon Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $4.58.

How much money does Lexicon Pharmaceuticals make?

Lexicon Pharmaceuticals has a market capitalization of $661.69 million and generates $24 million in revenue each year. The biopharmaceutical company earns $-58,570,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Lexicon Pharmaceuticals have?

Lexicon Pharmaceuticals employs 78 workers across the globe.

When was Lexicon Pharmaceuticals founded?

Lexicon Pharmaceuticals was founded in 1995.

What is Lexicon Pharmaceuticals' official website?

The official website for Lexicon Pharmaceuticals is

Where are Lexicon Pharmaceuticals' headquarters?

Lexicon Pharmaceuticals is headquartered at 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at (281) 863-3000 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.